AGL Stock Forecast 2025-2026
Distance to AGL Price Targets
AGL Price Momentum
10 Quality Stocks Worth Considering Now
Researching agilon health (AGL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AGL and similar high-potential opportunities.
Latest AGL Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, AGL has a neutral consensus with a median price target of $3.75 (ranging from $2.00 to $8.50). The overall analyst rating is Buy (6.4/10). Currently trading at $4.00, the median forecast implies a -6.3% downside. This outlook is supported by 3 Buy, 17 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Amir Farahan at Bernstein, projecting a 112.5% upside. Conversely, the most conservative target is provided by Craig Jones at Stifel, suggesting a 50.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AGL Analyst Ratings
AGL Price Target Range
Latest AGL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AGL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2025 | Baird | Michael Halloran | Neutral | Maintains | $5.00 |
| Apr 15, 2025 | TD Cowen | Ryan Langston | Hold | Maintains | $6.00 |
| Apr 8, 2025 | Bernstein | Amir Farahan | Outperform | Upgrade | $8.50 |
| Mar 21, 2025 | Needham | Ryan MacDonald | Hold | Reiterates | $0.00 |
| Feb 26, 2025 | RBC Capital | Sean Dodge | Outperform | Maintains | $3.50 |
| Feb 26, 2025 | Needham | Ryan MacDonald | Hold | Reiterates | $0.00 |
| Feb 26, 2025 | Citizens Capital Markets | Constantine Davides | Market Perform | Reiterates | $0.00 |
| Feb 26, 2025 | Stifel | Craig Jones | Hold | Maintains | $3.00 |
| Jan 15, 2025 | Bernstein | Amir Farahan | Market Perform | Maintains | $3.15 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Neutral | Upgrade | $2.25 |
| Jan 10, 2025 | Needham | Matthew Sheerin | Hold | Reiterates | $0.00 |
| Dec 16, 2024 | Macquarie | Tao Qiu | Neutral | Initiates | $3.00 |
| Dec 11, 2024 | Bernstein | Lance Wilkes | Market Perform | Initiates | $2.50 |
| Nov 19, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $3.00 |
| Nov 13, 2024 | Citigroup | Daniel Grosslight | Sell | Maintains | $1.75 |
| Nov 12, 2024 | Stifel | Craig Jones | Hold | Maintains | $2.00 |
| Nov 11, 2024 | Barclays | Andrew Mok | Underweight | Maintains | $2.00 |
| Nov 11, 2024 | JMP Securities | Constantine Davides | Market Perform | Downgrade | $0.00 |
| Nov 11, 2024 | TD Cowen | Gary Taylor | Hold | Maintains | $2.00 |
| Nov 8, 2024 | William Blair | Ryan Daniels | Market Perform | Downgrade | $0.00 |
Agilon Health Inc. (AGL) Competitors
The following stocks are similar to agilon health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Agilon Health Inc. (AGL) Financial Data
Agilon Health Inc. has a market capitalization of $1.65B with a P/E ratio of 0.0x. The company generates $6.06B in trailing twelve-month revenue with a -4.3% profit margin.
Revenue growth is +44.2% quarter-over-quarter, while maintaining an operating margin of -6.9% and return on equity of -44.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Agilon Health Inc. (AGL) Business Model
About Agilon Health Inc.
Provides technology-enabled healthcare services.
Agilon Health empowers primary care physicians to manage risk-based payment models, transitioning from fee-for-service to value-based care. The company generates revenue by partnering with physician practices, offering integrated data analytics and operational support to enhance patient care and reduce costs.
Headquartered in Ohio, Agilon Health plays a crucial role in the shift towards value-driven healthcare systems, focusing on proactive healthcare management and partnerships with leading medical groups to address the needs of population health management.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
1,076
CEO
Mr. Steven Jackson Sell
Country
United States
IPO Year
2021
Website
www.agilonhealth.comAgilon Health Inc. (AGL) Latest News & Analysis
Agilon (AGL) shares rose on high trading volume, and recent earnings estimate revisions indicate potential for future growth.
Agilon's rising share price and increased trading volume indicate strong investor interest, while positive earnings estimate revisions suggest potential future growth, signaling an attractive investment opportunity.
Agilon Health's stock is up 165% YTD in 2025, despite a 77% drop since its 2021 IPO. The rise is fueled by CMS rate hikes, but the company faces operating losses and industry challenges.
Agilon Health's stock surge amid CMS rate hikes signals potential recovery, but ongoing losses and industry challenges highlight risks. Its focus on value-based care could influence long-term growth.
Agilon Health, Inc. (NYSE: AGL) will participate in the BofA Securities 2025 Health Care Conference with a fireside chat on May 14 at 1:00 PM ET. A webcast will be available on their investor website.
Agilon Health's participation in a major healthcare conference signals potential growth opportunities and insights into its strategic direction, influencing investor sentiment and stock performance.
Agilon Health (NYSE: AGL) will release Q1 2025 financial results on May 6, 2025, after market close, followed by a conference call at 4:30 PM ET. Access details provided.
Agilon Health's upcoming financial results and conference call may influence stock prices, providing insights into performance and growth prospects, crucial for investment decisions.
J.P. Morgan analyst Lisa C. Gill updated her estimates for Agilon Health, Inc. (AGL) after the company's fourth-quarter results, maintaining a Neutral rating.
J.P. Morgan's Neutral rating and updated estimates reflect cautious sentiment on Agilon Health, potentially influencing investor confidence and stock performance.
Agilon Health (AGL) and Paragon 28, Inc. (FNA) have shown performance metrics relative to their sector for the current year. Specific performance details were not provided.
Performance comparison against sector benchmarks helps investors gauge relative strength, assess risk, and make informed decisions about their investment strategies in Agilon Health and Paragon 28.
Frequently Asked Questions About AGL Stock
What is Agilon Health Inc.'s (AGL) stock forecast for 2025?
Based on our analysis of 27 Wall Street analysts, Agilon Health Inc. (AGL) has a median price target of $3.75. The highest price target is $8.50 and the lowest is $2.00.
Is AGL stock a good investment in 2025?
According to current analyst ratings, AGL has 3 Buy ratings, 17 Hold ratings, and 2 Sell ratings. The stock is currently trading at $4.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AGL stock?
Wall Street analysts predict AGL stock could reach $3.75 in the next 12 months. This represents a -6.3% decrease from the current price of $4.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Agilon Health Inc.'s business model?
Agilon Health empowers primary care physicians to manage risk-based payment models, transitioning from fee-for-service to value-based care. The company generates revenue by partnering with physician practices, offering integrated data analytics and operational support to enhance patient care and reduce costs.
What is the highest forecasted price for AGL Agilon Health Inc.?
The highest price target for AGL is $8.50 from Amir Farahan at Bernstein, which represents a 112.5% increase from the current price of $4.00.
What is the lowest forecasted price for AGL Agilon Health Inc.?
The lowest price target for AGL is $2.00 from Craig Jones at Stifel, which represents a -50.0% decrease from the current price of $4.00.
What is the overall AGL consensus from analysts for Agilon Health Inc.?
The overall analyst consensus for AGL is neutral. Out of 27 Wall Street analysts, 3 rate it as Buy, 17 as Hold, and 2 as Sell, with a median price target of $3.75.
How accurate are AGL stock price projections?
Stock price projections, including those for Agilon Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.